Evidence map›Paper›PMID 36547746›Full record

ArticleUrolithiasis2022

Osteopontin phosphopeptide mitigates calcium oxalate stone formation in a Drosophila melanogaster model.

Polycronis P Akouris, John A Chmiel, Gerrit A Stuivenberg, Wongsakorn Kiattiburut, Jennifer Bjazevic, Hassan Razvi, Bernd Grohe, Harvey A Goldberg, Jeremy P Burton, Kait F Al

Abstract read
PubMed Publisher
In one paragraph

Article in Urolithiasis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Frontiers in physiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Polycronis P AkourisCanadian Centre for Human Microbiome and Probiotics, London, ON, Canada.
John A ChmielCanadian Centre for Human Microbiome and Probiotics, London, ON, Canada.
Gerrit A StuivenbergCanadian Centre for Human Microbiome and Probiotics, London, ON, Canada.
Wongsakorn KiattiburutCanadian Centre for Human Microbiome and Probiotics, London, ON, Canada.
Jennifer BjazevicDivision of Urology, Department of Surgery, Western University, London, ON, Canada.
Hassan RazviDivision of Urology, Department of Surgery, Western University, London, ON, Canada.
Bernd GroheCanadian Centre for Human Microbiome and Probiotics, London, ON, Canada.
Harvey A GoldbergDepartment of Biochemistry, Western University, London, ON, Canada.
Jeremy P BurtonCanadian Centre for Human Microbiome and Probiotics, London, ON, Canada.
Kait F AlCanadian Centre for Human Microbiome and Probiotics, London, ON, Canada. kal@uwo.ca.
Western University · CACanadian Science Centre for Human and Animal Health · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney stone disease affects nearly one in ten individuals and places a significant economic strain on global healthcare systems. Despite the high frequency of stones within the population, effective preventative strategies are lacking and disease prevalence continues to rise. Osteopontin (OPN) is a urinary protein that can inhibit the formation of renal calculi in vitro. However, the efficacy of OPN in vivo has yet to be determined. Using an established Drosophila melanogaster model of calcium oxalate urolithiasis, we demonstrated that a 16-residue synthetic OPN phosphopeptide effectively reduced stone burden in vivo. Oral supplementation with this peptide altered crystal morphology of calcium oxalate monohydrate (COM) in a similar manner to previous in vitro studies, and the presence of the OPN phosphopeptide during COM formation and adhesion significantly reduced crystal attachment to mammalian kidney cells. Altogether, this study is the first to show that an OPN phosphopeptide can directly mitigate calcium oxalate urolithiasis formation in vivo by modulating crystal morphology. These findings suggest that OPN supplementation is a promising therapeutic approach and may be clinically useful in the management of urolithiasis in humans.

Indexed as

Calcium OxalateKidney CalculiOsteopontinPhosphopeptidesAnimalsDisease Models, AnimalDrosophila melanogasterCalcium OxalateOsteopontinPhosphopeptidesCalcium oxalateCrystal formation inhibitorDrosophila melanogasterOsteopontinUrolithiasis

Identifiers

PMID36547746
OpenAlexW4312184630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.